ATE446101T1 - Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung - Google Patents

Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Info

Publication number
ATE446101T1
ATE446101T1 AT04075413T AT04075413T ATE446101T1 AT E446101 T1 ATE446101 T1 AT E446101T1 AT 04075413 T AT04075413 T AT 04075413T AT 04075413 T AT04075413 T AT 04075413T AT E446101 T1 ATE446101 T1 AT E446101T1
Authority
AT
Austria
Prior art keywords
senil
dementia
alzheimer
disease
treatment
Prior art date
Application number
AT04075413T
Other languages
English (en)
Inventor
David John Kyle
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22114083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446101(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Application granted granted Critical
Publication of ATE446101T1 publication Critical patent/ATE446101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
AT04075413T 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung ATE446101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7350593A 1993-06-09 1993-06-09

Publications (1)

Publication Number Publication Date
ATE446101T1 true ATE446101T1 (de) 2009-11-15

Family

ID=22114083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Country Status (11)

Country Link
EP (3) EP0707487B1 (de)
JP (3) JPH08511533A (de)
AT (2) ATE264099T1 (de)
AU (1) AU693450B2 (de)
CA (2) CA2164291C (de)
DE (2) DE69433713T2 (de)
DK (1) DK0707487T3 (de)
ES (2) ES2335991T3 (de)
MX (1) MX263227B (de)
PT (1) PT707487E (de)
WO (1) WO1994028913A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5583019A (en) 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
EP0823475B1 (de) * 1995-04-17 2009-06-17 National Institute of Advanced Industrial Science and Technology Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
DK0894142T4 (da) * 1996-03-28 2014-02-24 Dsm Ip Assets Bv Mikrobiel olie der omfatter en polyumættet fedtsyre og proces til produktion af olie fra pasteuriseret og granuleret biomasse.
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
EP0904339B2 (de) * 1996-05-15 2006-09-20 DSM IP Assets B.V. Verfahren zum extrahieren von sterol mit einem polaren lösungsmittel zur herstellung eines mikrobiellen öles mit niedrigem sterolgehalt
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP3792309B2 (ja) 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
FR2782921B1 (fr) 1998-09-09 2002-09-20 Dior Christian Parfums Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique
WO2000021524A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Pufa supplements
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1178103A1 (de) 2000-08-02 2002-02-06 Dsm N.V. Reinigung von rohen PUFA-reichen Ölen
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
CN101837138B (zh) 2002-06-19 2014-05-28 帝斯曼知识产权资产管理有限公司 微生物油
EP2295529B2 (de) 2002-07-11 2022-05-18 Basf As Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2384750A1 (de) 2002-09-27 2011-11-09 Martek Biosciences Corporation Verbesserte Glykämiesteuerung für Prädiabetes und/oder Diabetes Typ III mithilfe von Docohexansäure
NZ539624A (en) 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US20090054523A1 (en) * 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
PL1888081T3 (pl) * 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
FR2894772B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Procede d'enrichissement en dha
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
EP2098229A4 (de) 2006-12-28 2010-03-10 Suntory Holdings Ltd Nervenregenerationsmittel
DE102007031039A1 (de) * 2007-07-04 2009-01-08 Süd-Chemie AG Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde
WO2010088700A1 (en) * 2009-02-02 2010-08-05 Martek Biosciences Corporation Methods for improving cognitive function and decreasing heart rate
DK2408922T3 (en) 2009-03-19 2016-12-05 Dsm Ip Assets Bv Thraustochytrids, FATTY ACID COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
EP3617318A1 (de) * 2010-06-01 2020-03-04 DSM IP Assets B.V. Extraktion von lipiden aus zellen und produkte daraus
WO2012090625A1 (ja) * 2010-12-28 2012-07-05 医療法人社団ブックス 認知症を血液サンプルで判定するための検査方法
JP2014515928A (ja) 2011-05-19 2014-07-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 認知機能減退に対する医療食品
EA034980B1 (ru) * 2011-07-21 2020-04-14 ДСМ АйПи АССЕТС Б.В. Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции жирных кислот, способы их получения и применения
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
FR2991337B1 (fr) * 2012-05-29 2016-09-02 Roquette Freres Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues
ES2749002T3 (es) 2013-12-20 2020-03-18 Mara Renewables Corp Métodos de recuperación de aceite sobre microorganismos
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
PL3541783T3 (pl) 2016-11-17 2024-03-04 University Of Debrecen Związki prekursorowe do dostarczania retinoidów szlaku witaminy a5 i ich zastosowania
KR101946362B1 (ko) * 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
AU2122688A (en) * 1987-07-20 1989-02-13 Maricultura, Incorporated Microorganism production of omega-3 (n-3) lipids
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JP2730081B2 (ja) * 1988-09-24 1998-03-25 日本油脂株式会社 微生物によるアラキドン酸含有油脂の製造方法
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
NZ241359A (en) * 1991-01-24 1994-08-26 Martek Corp Supplementation of infant formula by the addition of at least two different polyunsaturated fatty acids obtained from at least two different microbial sources; compositions comprising such oils
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2121986A1 (en) * 1993-04-26 1994-10-27 Daizo Takeuchi Processes for culturing marine microalgae and producing docosahexaenoic acid using the same

Also Published As

Publication number Publication date
JP2008133286A (ja) 2008-06-12
CA2596241A1 (en) 1994-12-22
ES2218525T3 (es) 2004-11-16
AU6963594A (en) 1995-01-03
EP0707487A4 (de) 1998-09-02
ATE264099T1 (de) 2004-04-15
ES2335991T3 (es) 2010-04-07
CA2596241C (en) 2011-04-19
EP0707487A1 (de) 1996-04-24
JP2011121978A (ja) 2011-06-23
WO1994028913A1 (en) 1994-12-22
EP1419780B1 (de) 2009-10-21
PT707487E (pt) 2004-08-31
DE69433713T2 (de) 2005-04-07
CA2164291A1 (en) 1994-12-22
DK0707487T3 (da) 2004-08-02
EP0707487B1 (de) 2004-04-14
DE69435246D1 (de) 2009-12-03
CA2164291C (en) 2007-10-30
DE69433713D1 (de) 2004-05-19
JPH08511533A (ja) 1996-12-03
EP2140863A1 (de) 2010-01-06
AU693450B2 (en) 1998-07-02
EP1419780A1 (de) 2004-05-19
MX263227B (en) 2008-12-17

Similar Documents

Publication Publication Date Title
ATE446101T1 (de) Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
ATE210979T1 (de) Verwendung rapamycin zur herstellung eines medikaments für die verbeugung und behandlung von hyperproliferativen gefässerkrankheiten, eventuell in kombination mit mycophenolsäure
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
ATE79264T1 (de) Verwendung von bismuth zur herstellung von medikamenten zur behandlung von magendarmst¯rungen, die von campylobacter polyridis verursacht sind.
DE69012591T2 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
WO1996040106A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
DE3855527D1 (de) Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
DE69426622T2 (de) Verwendung von triazinverbindungen zur herstellung eines arzneimittels zur behandlung von erinnerungs-und lernstörungen
SE8700136D0 (sv) Forfarande for behandling av amfotera aminosyror
ATE168558T1 (de) Verwendung von chinonen zur herstellung eines arzneimittels zur vorbeugung und behandlung von allergischer rhinitis
ATE145133T1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)- ester-verbindungen zur herstellung eines arzneimittels zur behandlung der neuromuskuläre inkontinenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties